Table 1.
Mushroom | Bioactive Compound | Pro-Health Effects | References |
---|---|---|---|
A. bisporus (Common white) | Phenolics e.g., Ergothioneine | Antioxidant; increased ORAC activity; increased adiponectin; reduced AGEs; increased glutathione reductase and catalase activities | [63,70,86] |
Polysaccharides | Gut microbiota regulation; intestinal barrier integrity | [25] | |
Secondary metabolites | Anti-hyperglycaemic; inhibitory effects on LDL oxidation; reduced HMG-CoA reductase activity; LPS reduction; ACE2 inhibition; cardiometabolic parameters improvement | [30,66,79,80] | |
Andosan™ | Ergosterol | Cytotoxic | [51] |
Commercial extract AbM + H. erinaceus and G. frondosa |
Immunomodulatory; anti-inflammatory; anti-tumour |
[49] | |
Tomeka™ | Commercial extract A. bisporus + soy |
Anti-pathogenic | [3,29] |
C. militaris (Cordyceps) | Cordycepin | Antiviral; RNA synthesis inhibition; suppressed EB viral replication; cytotoxic | [14,41] |
Antioxidant; anti-hyperlipidaemic; hepatoprotective | [81] | ||
SCFAs | Immune regulation and health promoting | [25] | |
F. velutipes (Enoki) | Polysaccharides/dietary fibre | Reduced cardiometabolic parameters | [83] |
Antioxidant | Mycosterol | [83] | |
G. frondosa (Maitake) | Polysaccharides | Anti-inflammatory; antioxidant; immunomodulatory | [31,53] |
Increased insulin sensitivity; decreased systolic BP; decreased RAAS; increased NO | [82] | ||
G. lucidum (Reishi) | Polysaccharides | SCFAs production; gut microbiota regulation; anti-obesity; anti-inflammation; reduced metabolic endotoxaemia; decreased FBG and insulin levels | [87,89,90,91] |
Ganodermic compounds—triterpenoids, other phenolics | Antioxidant; atherosclerotic plaque attenuation; anti-tumour; anti-inflammation; antiviral HIV-1 and HIV-1 protease inhibition | [30,42,56,64,84] | |
Mycelia fractions | ACE inhibition | [73] | |
H. erinaceus (Lion’s Mane) | Mycelia polysaccharide fractions | Anti-hyperglycaemic; improved antioxidant enzymatic activities | [69,80] |
Fruiting body solvent fractions | LDL oxidation inhibition; HMG-CoA reductase inhibition | ||
L. edodes (Shiitake) | Polysaccharides; -glucans | Antiviral; antioxidant; immunomodulatory; cytotoxic; anti-inflammatory; microbiome regulation | [1,2,6,17,25,44] |
Aqueous extract | Anti-bacterial; anti-fungal | [43] | |
Lovastatin | Hypolipidaemic | [76] | |
P. ostreatus (Oyster) | -glucans-pleuran | Immunomodulatory | [36,46,47,48] |
Lectins | Vaccine adjuvant | [20,45] | |
Phenolics, peptides | ACE2 inhibition | [30,75] | |
Lovastatin | HMG-CoA reductase inhibition | [75,76,77] | |
Polysaccharides | Cardiometabolic parameter improvements | [75,78] | |
T. versicolor (Turkey Tail) | PSP, PSK | Cancer therapy/adjuvants; Immunomodulatory | [57,59,60,61] |
Gut microbiota modulation | [25] | ||
Glucans, phenolics | Antioxidant | [62] |